Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of TAS-115 (pamufetinib) in advanced solid tumors
jRCT2080222284Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamufetinib in Nonhematologic neoplasms and prostate cancer (PCa) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS-115, Maximum tolerated dose (MTD) and 1 more. Started Nov 2013; status: completed.
02
Drugs
pamufetinib
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080222284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222284.